John Bender, MD
Family Medicine · Fort Collins, CONPI 1609864065
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,495 of the $5,095 with a category attached, or 88.2%. It is spread thinly across 46 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,292 and has fallen 58.3% since, to $538 in 2025. Among family medicine clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 211 payments — averaging $24.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Eko Health, Inc.$600
- Abbott$597
- Neurocrine Biosciences, Inc.$291
- Pfizer$230
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$204
- plus $2K from 40 others
Across 1 payment — averaging $16,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$17K
What the payments were for
- Speaking & faculty fees$60012%
- Food & beverage$4,49588%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,095 in reported general payments places this provider in the 90th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 12 | $104,478 |
| Humira(Cf) PenAdalimumab | 12 | $78,474 |
| ForteoTeriparatide | 13 | $55,769 |
| XareltoRivaroxaban | 48 | $54,009 |
| OzempicSemaglutide | 32 | $45,828 |
| EliquisApixaban | 38 | $39,008 |
| ProliaDenosumab | 12 | $20,560 |
| MyrbetriqMirabegron | 17 | $10,986 |
| JanuviaSitagliptin Phosphate | 15 | $10,325 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 46 | $10,307 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 31 | $10,125 |
| Oxycodone Hcl | 101 | $3,376 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $2,452 |
| Fenofibrate | 21 | $2,292 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 31 | $2,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo | $87 | $55,76913 claims |
| Johnson & JohnsonXarelto | $90 | $54,00948 claims |
| PfizerEliquis, Abrysvo | $230 | $49,13369 claims |
| Novo NordiskOzempic | $120 | $45,82832 claims |
| AmgenProlia | $135 | $20,56012 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $10,98617 claims |
| MerckJanuvia | $71 | $10,32515 claims |
| GSKShingrix | $197 | $10,30746 claims |
| AbbVieSynthroid | $1,191 | $97912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Fort Collins
- Ethan LazarusDenver$688K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Mark DeutchmanDenver$258K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
- Lawrence AndrewsColorado Springs$102K
- Gregory MaederWestminster$95K
- Paul SimmonsGrand Junction$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.